Enzalutamide (Xtandi) and abiraterone (Zytiga) may have similar effectiveness in metastatic castration-sensitive prostate cancer

1. The use of enzalutamide (Xtandi) and abiraterone (Zytiga) in metastatic castration-sensitive prostate cancer (mCSPC) was associated with similar overall survival (OS). 2. The use of enzalutamide was associated with an improved OS among patients over the age of 75 years. Evidence Rating Level: 2 (Good) Enzalutamide and abiraterone are two androgen-receptor pathway inhibitors (ARPI) […] The post…